SURUNKALI BUYRAK ETISHMOVCHILIGIDA ANEMIYA RIVOJLANISHINING PATOFIZIOLOGIYASI
Article Sidebar
Main Article Content
Аннотация:
Jahon Sog‘liqni saqlash tashkiloti (JSST) statistik ma'lumotlariga ko'ra, dunyo aholisining taxminan 13% ga yaqinida surunkali buyrak kasalliklaridan (SBK) aziyat chekib kelmoqda. Bugungi kunda qandli diabet, arterial gipertenziya, semizlik va boshqa lipidlar almashinuvining buzilishi bilan kechadigan kasalliklar SBK rivojlanishining asosiy sababi bo’lib, SBK bilan og'rigan 4 bemordan 3 tasining anamnezida ushbu kassaliklari mavjudligi aniqlangan. SBK - buyraklar samarali ishlash qobiliyatini asta-sekin yo'qotadigan progressiv holat. Bu organizmda toksinlar to'planishiga, suv va elektrolitlar muvozanatining buzilishiga va boshqa sog'liq muammolariga olib keladi. Surunkali buyrak etishmovchiligi (SBY) yoki Surunkali buyrak kasalligi hozirgi kunda yurak-qon tomir kasalliklari va o'lim xavfining ortishiga olib keluvchi butun jahon sog'liqni saqlash soxasining jiddiy muammosi hisoblanadi.
Article Details
Как цитировать:
Библиографические ссылки:
Pradeep Arora., Chief Editor., Vecihi Batuman. Chronic Kidney Disease. Medscape. Feb 11, 2025 y.
Tregub P.P., Kulikov V.P., Malinovskaya N.A., Kuzovkov D.A., Kovzelev P.D. HIF-1 – alternative signal pathways of activation and formation of tolerance to hypoxia/ischemia. Pathological Physiology and Experimental Therapy, Russian journal. 2019; 63 (4).
Demet Kivanc Izgi1ab, Suleyman Rustu Oguz. Exploring the Interplay of Hypoxia-Inducible Factors: Unveiling Genetic Connections to Diseases Through Bioinformatics Analysis. Medical Science and Discovery, 2023; 10(9):669-672
P Carmeliet, Y Dor, J M Herbert, D Fukumura, K Brusselmans, M et.all. Role of HIF-1alpha in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis. Nature 1998 Oct 1;395(6701):525
Robert Provenzano., Anatole Besarab., Chao H Sun., Susan A Diamond., John H Durham., Jose L Cangiano., Joseph R Aiello et all/Oral Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor Roxadustat (FG-4592) for the Treatment of Anemia in Patients with CKD. 2016 by the American Society of Nephrology. National Library of Medicine 2016 Jun 6;11(6):982-991.
Joshua M Kaplan., Neeraj Sharma., Sean Dikdan. Hypoxia-Inducible Factor and Its Role in the Management of Anemia in Chronic Kidney Disease. International Journal of Molecular Sciences. 2018 Jan 29;19(2):389.
Drevytska T., Gavenauskas B., Drozdovska S., Nosar V., Dosenko V., Mankovska I. HIF-α mRNA expression changes in different tissues and their role in adaptation to intermittent hypoxia and physical exercise. Pathophysiology. 2012;19: 205–214.
Badridinova B.K. Bakayev E.S. Osobennosti medikamentoznoy terapii anemii pri xronicheskoy bolezni pochek. Central Asian Journal of Medical and Natural Science. vol. 4 no. 5 (2023): September.
Webster AC, Nagler EV, et.all/ P. Chronic kidney disease. Lancet. (2017) 389:1238–52.
Yousuf Abdulkarim Waheed, Jie Liu, Shifaa Almayahe, Dong Sun. The role and clinical implications of HIF-PHI daprodustat in dialysis-dependent and non-dialysis-dependent chronic kidney disease anemic patients: a general review. Front. Nephrol., 2024 Dec 23;4:
Andrew D Nguyen., Jeffrey G McDonald., Richard K Bruick., Russell A DeBose-Boyd. Hypoxia stimulates degradation of 3-hydroxy-3-methylglutaryl-coenzyme A reductase through accumulation of lanosterol and hypoxia-inducible factor-mediated induction of insigs. Journal of Biological Chemistry 2007 Sep 14;282(37):27436-27446.
Seonghwan Hwang., Andrew D Nguyen., Youngah Jo., Luke J Engelking., James Brugarolas., Russell A DeBose-Boyd. Hypoxia-inducible factor 1α activates insulin-induced gene 2 (Insig-2) transcription for degradation of 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase in the liver. Journal of Biological Chemistry 017 Jun 2;292(22):9382-9393.
Dickson AS, Pauzaite T, Arnaiz E, Ortmann BM, West JA, Volkmar N, Martinelli AW, Li Z, Wit N, Vitkup D, Kaser A, Lehner PJ, Nathan JA. A HIF independent oxygen-sensitive pathway for controlling cholesterol synthesis. Nature Commun. 2023 Aug 9;14(1):4816.
Andrew S Levey., Kai-Uwe Eckardt., Nijsje M Dorman., ey all. Nomenclature for kidney function and disease: report of a Kidney Disease: Improving Global Outcomes (KDIGO) Consensus Conference. Kidney international 2020 Jun;97(6):1117-1129.
Richard L Amdur., Harold I Feldman., Jayanta Gupta., Wei Yang. Inflammation and Progression of CKD: The CRIC Study. Clinical Journal of the American Society of Nephrology. 2016 Sep 7;11(9):1546-1556.
Chapter 1: Definition and classification of CKD. Kidney Int Suppl (2011). 2013 Jan;3(1):19-62.
Inker LA, Astor BC, Fox CH, Isakova T, Lash JP, Peralta CA, Kurella Tamura M, Feldman HI. KDOQI US commentary on the 2012 KDIGO clinical practice guideline for the evaluation and management of CKD. Am J Kidney Dis. 2014 May;63(5):713-353.
Webster AC, Nagler EV, Morton RL, Masson P. Chronic Kidney Disease. Lancet. 2017 Mar 25;389(10075):1238-1252.
Textor SC. Ischemic nephropathy: where are we now? J Am Soc Nephrol. 2004 Aug;15(8):1974-82.
Kitamoto Y, Tomita M, Akamine M, Inoue T, Itoh J, Takamori H, Sato T. Differentiation of hematuria using a uniquely shaped red cell. Nephron. 1993;64(1):32-6.